Approval for Hypertension Polypill

Article

The US Food and Drug Administration (FDA) has approved a polypill for hypertension, a combination of perindopril arginine and amlodipine (Prestalia/ Symplmed Pharma-Servier).

The US Food and Drug Administration (FDA) has approved a polypill for hypertension, a combination of perindopril arginine and amlodipine (Prestalia/ Symplmed Pharma-Servier).

The approval was based on data from a trial involving 837 patients. The study showed that a fixed-dose combination of the two drugs in a single pill “was significantly better than either compound alone in reducing both sitting diastolic and sitting systolic blood pressure after six weeks of treatment,” the company announced.

Other studies have shown that using these drugs together may reduce cardiovascular events.

George Bakris, MD, principal investigator in the trial of the drug, known as PATH, called Prestalia “another great combination of two drugs each with an evidence based outcome history.”

The drug combines perindopril arginine, and angiotensin converting enzyme inhibitor and amlodipine, a calcium channel blocker. It is meant to treat hypertension and may be used in patients whose blood pressure is not adequately control on monotherapy. By lowering blood pressure, the risk of cardiovascular events is reduced. But the company said there are no controlled trials demonstration the degree of that risk reduction.

Prestalia is contraindicated in patients with hereditary or idiopathic angioedema, with or without previous ACE inhibitor treatment. The drug should be immediately discontinued should a patient’s pregnancy be discovered. It is toxic to the developing fetus and can result in fetal injury or death.

Related Videos
Video 2 - "Lessons from EXPLORER-HCM: Unveiling CMIs' Potential in oHCM Treatment "
Video 1 - "Novel Cardio Myosin Inhibitors Targeting Obstructive Hypertrophic Cardiomyopathy's Root Cause "
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Heart Failure Treatment Outcomes and Contraindications
Patient Involvement in Advanced HF Treatment, with Ashley Malliett, DMSc, MPAS, PA-C
Tailoring Chest Pain Diagnostics to Patients, with Kyle Fortman, PA-C, MBA
Kyle Fortman, PA-C, MBA: Troponin and Heart Injury Risk Screening Recommendations
What Should the American Academy of Physician Associates Focus on in 2025?
The Rising Rate of Heat-Related Illness, with Janelle Bludhorn, PA-C
© 2024 MJH Life Sciences

All rights reserved.